Literature DB >> 2468911

Cardiovascular drugs and atherosclerosis: effects of calcium antagonists, beta-blockers, and nitrates on atherosclerotic characteristics of human aortic cells.

A N Orekhov1, G N Baldenkov, V V Tertov, L H Ryong, S G Kozlov, A A Lyakishev, V A Tkachuk, V N Smirnov.   

Abstract

Primary cell culture derived from atherosclerotic plaque of human aorta was used to assess direct effects of calcium antagonists, beta-blockers, and nitrates on vessel wall cells. Within 24 h, calcium antagonists (verapamil, nifedipine, darodipine, isradipine, diltiazem, etc.) reduced the cholesterol level in cultured cells. Furthermore, these agents decreased the incorporation of [3H]thymidine. Thus, the calcium antagonists manifested direct antiatherosclerotic action in culture by normalizing major manifestations of atherosclerosis at the cellular level. On the other hand, beta-blockers (propranolol, alprenolol, metoprolol, atenolol, pindolol, and timolol) caused a 1.5- to twofold rise in cholesterol level of cultured cells and stimulated their proliferation. Nitrates (nitroglycerin, isosorbide dinitrate, and nitroprusside) had no effect on atherosclerotic characteristics. Within 2-4 h after a single dose of oral administration of beta-blocker (propranolol), patients' blood plasma turned atherogenic, i.e., its addition to culture-induced cholesterol accumulation and stimulated proliferation. At the same time, blood plasma of patients who received calcium antagonists (verapamil and nifedipine) acquired antiatherosclerotic properties manifested in its ability to lower the intracellular cholesterol level and inhibit proliferative activity of cultured cells. These findings allow the assumption that not only in vitro, but in vivo as well, calcium antagonists and beta-blockers are antiatherosclerotic and atherogenic drugs, respectively.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2468911

Source DB:  PubMed          Journal:  J Cardiovasc Pharmacol        ISSN: 0160-2446            Impact factor:   3.105


  9 in total

1.  Use of human atherosclerotic cells for optimization of antiatherosclerotic therapy.

Authors:  A N Orekhov
Journal:  Agents Actions       Date:  1991-01

2.  Evolution of insulin resistance in coronary artery disease patients on four different pharmacological therapies.

Authors:  G Piédrola; E Novo; J Serrano-Gotarredona; M L de Teresa; R García-Robles
Journal:  Postgrad Med J       Date:  1999-01       Impact factor: 2.401

Review 3.  Verapamil. An updated review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in hypertension.

Authors:  D McTavish; E M Sorkin
Journal:  Drugs       Date:  1989-07       Impact factor: 9.546

Review 4.  Verapamil: a review of its pharmacological properties and therapeutic use in coronary artery disease.

Authors:  R N Brogden; P Benfield
Journal:  Drugs       Date:  1996-05       Impact factor: 9.546

Review 5.  Report of the Canadian Hypertension Society Consensus Conference: 3. Pharmacologic treatment of essential hypertension.

Authors:  R I Ogilvie; E D Burgess; J R Cusson; R D Feldman; L A Leiter; M G Myers
Journal:  CMAJ       Date:  1993-09-01       Impact factor: 8.262

6.  Use of cell culture for optimisation of direct antiatherogenic therapy with verapamil.

Authors:  A N Orekhov; E M Pivovarova; I A Sobenin; V V Yakushkin; V V Tertov
Journal:  Drugs       Date:  1992       Impact factor: 9.546

7.  Testing of serum atherogenicity in cell cultures: questionable data published.

Authors:  Sergei V Jargin
Journal:  Ger Med Sci       Date:  2012-01-31

Review 8.  Soy and phytoestrogens: possible side effects.

Authors:  Sergei V Jargin
Journal:  Ger Med Sci       Date:  2014-12-15

9.  Chronic Kidney Disease Progression Risk in Patients With Diabetes Mellitus Using Dihydropyridine Calcium Channel Blockers: A Nationwide, Population-Based, Propensity Score Matching Cohort Study.

Authors:  Shih-Yi Lin; Cheng-Li Lin; Cheng-Chieh Lin; Wu-Huei Hsu; Chung-Y Hsu; Chia-Hung Kao
Journal:  Front Pharmacol       Date:  2022-03-09       Impact factor: 5.810

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.